NeuroSense Regains NASDAQ Compliance, Secures ALS Drug Patent
Ticker: NRSNW · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Sep 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: compliance, patent, pharmaceuticals, ALS
TL;DR
NeuroSense back on NASDAQ, got a patent for ALS drug PrimeC.
AI Summary
On September 24, 2024, NeuroSense Therapeutics Ltd. announced it has regained compliance with the NASDAQ minimum bid price rule. Additionally, the company was granted a key U.S. patent for its novel PrimeC formulation, which is its lead asset for Amyotrophic Lateral Sclerosis (ALS).
Why It Matters
Regaining NASDAQ compliance is crucial for continued stock exchange listing, while the new patent strengthens the intellectual property protection for their ALS treatment.
Risk Assessment
Risk Level: medium — While regaining compliance and securing a patent are positive, the company's success still hinges on the clinical development and market acceptance of its lead asset.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filing company
- NASDAQ (company) — Stock exchange
- PrimeC (drug) — Lead asset for ALS
- Amyotrophic Lateral Sclerosis (ALS) (disease) — Targeted condition
- September 24, 2024 (date) — Date of announcements
FAQ
What is the significance of regaining compliance with the NASDAQ Minimum Bid Price Rule?
Regaining compliance with the NASDAQ Minimum Bid Price Rule is significant because it allows NeuroSense Therapeutics Ltd. to maintain its listing on the NASDAQ stock exchange, avoiding potential delisting.
What is the key U.S. patent granted to NeuroSense Therapeutics?
NeuroSense Therapeutics was granted a key U.S. patent for its novel PrimeC formulation, which is its lead asset for Amyotrophic Lateral Sclerosis (ALS).
What is the primary indication for NeuroSense's lead asset, PrimeC?
The primary indication for NeuroSense's lead asset, PrimeC, is Amyotrophic Lateral Sclerosis (ALS).
When were these announcements made by NeuroSense Therapeutics?
Both announcements, regarding regaining NASDAQ compliance and the patent grant, were made on September 24, 2024.
What form is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 339 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-09-24 09:25:02
Filing Documents
- ea0215474-6k_neurosense.htm (6-K) — 12KB
- ea021547401ex99-1_neurosense.htm (EX-99.1) — 8KB
- ea021547401ex99-2_neurosense.htm (EX-99.2) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 26KB
- ex99-2_001.jpg (GRAPHIC) — 9KB
- 0001213900-24-081228.txt ( ) — 86KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: September 24, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3